Nucleo(s/t)ide analogs (NAs) and interferon-alpha (IFN-α) are currently the main drugs for the clinical treatment of chronic hepatitis B. NAs can effectively control HBV replication, but it requires long-term medication and discontinuation is prone to lead to relapse. The gene discussed is IFNA2; the disease is chronic hepatitis B virus infection.